ASH 2022 | Impact of comorbidities & patient preference in treatment selection for elderly patients with CLL
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, comments on the importance of considering comorbidities and patient preferences when selecting a chemotherapy-free treatment regimen for elderly patients with chronic lymphocytic leukemia (CLL). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
MSD: Consultancy, Honoraria; Roche: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; BeiGene: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Lilly/Loxo: Consultancy, Honoraria.
